Castle Biosciences Inc. (CSTL) Reports Prelim Q4 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results
January 8, 2023 7:00 PM EST2022 total revenue expected to meet or exceed top end of guided range of $132137 million
Delivered 44,338 total test reports in 2022, an increase of 58% compared to 2021
Growth of 37% year over year in DecisionDx®-Melanoma test report volume
Year-end 2022 cash, cash equivalents and marketable investment securities expected to be approximately $259 million
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results... More
